Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$35.91 -2.04%

-$1.24 today

Market cap
$1.03B
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Nektar TherapeuticsNASDAQ: NKTR

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin narrows to -417.9%

Operating margin was -417.9% in Q2 FY2026, down 93.7 pp from a year earlier. On a trailing-twelve-month basis it was -240.4%, down 105.9 pp year over year. Over 3 fiscal years it widened by 24.2 pp.

Context

  • Operating margin widened in 2 of the last 3 fiscal years.

What to watch

Whether operating margin reaches the consensus estimate from 13 analysts of -248.6% for the fiscal year ending Dec 2026, down from -236.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-417.9%-65.7 pp QoQ
Last fiscal yearDec 2025
-236.8%-129.9 pp YoY
LTMJun 2026
-240.4%-105.9 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-93.7 pp-355.1 pp-261.4 pp
1 year-129.9 pp-11.8 pp+118.1 pp
3 years+24.2 pp-103.5 pp-127.7 pp
5 years+206.1 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-236.8%
Year-over-year change
-129.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How NKTR compares with its peers on the latest reported figures

  • NKTR's LTM Jun 2026 operating margin of -240.4% is the 5th highest of the 10 companies compared; the peer median is -362.1%.
  • Its year-over-year change of -105.9 pp is the 4th highest of 9, against a peer median of -207.3 pp.
  • Over three fiscal years its change of +24.2 pp compares with a peer median of -36.5 pp.
NKTR Competitors Peer median
Operating Margin for NKTR and competitors
Company Period LTM level YoY 3-year change
CGENCompugen Ltd.LTM Mar 202642.3% +95.9 pp+514.7 pp
IMCRImmunocore Holdings plcLTM Mar 2026-7.6% +6.7 pp+18.3 pp
MGNXMacroGenics, Inc.LTM Mar 2026-40.5% +24.7 pp+32.2 pp
XNCRXencor, Inc.LTM Jun 2026-205.8% -128.2 pp-91.2 pp
NKTRNektar TherapeuticsLTM Jun 2026-240.4% -105.9 pp+24.2 pp
CHRSCoherus Oncology, Inc.LTM Mar 2026-362.1% -304.1 pp-304.0 pp
RCUSArcus Biosciences, Inc.LTM Jun 2026-415.4% -286.4 pp+93.7 pp
IMTXImmatics N.V.LTM Mar 2026-570.3% -528.3 pp-394.4 pp
ANLAdlai Nortye Ltd.LTM Jun 2024-996.4% ——
IPHAInnate Pharma S.A.FY2025-1916.9% -1508.3 pp-1817.4 pp
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding NKTR) -362.1%-207.3 pp-36.5 pp

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue101.91M92.06M90.12M98.43M55.23M
Cost of Revenue24.9M21.64M36.64M30.69M0
Gross Profit77.01M70.42M53.48M67.74M55.23M
Gross Margin75.6%76.5%59.3%68.8%100.0%
Research & Development400.27M218.32M114.16M120.91M117.33M
Selling, General & Admin122.84M92.33M77.42M76.75M68.67M
Operating Expenses523.11M310.66M190.9M172.94M186M
Depreciation & Amortization14.15M12.2M7.82M4.39M1.03M
EBITDA(461.82M)(323.87M)(243.11M)(86.7M)(137M)
EBITDA Margin-453.2%-351.8%-269.8%-88.1%-248.1%
Operating Income(446.1M)(240.24M)(137.43M)(105.2M)(130.77M)
Operating Margin-437.8%-261.0%-152.5%-106.9%-236.8%
Interest Income2.73M6.78M19.01M14.5M10.44M
Interest Expense47.31M28.91M25.33M28.11M26.18M
Other Income / Expenses(77.18M)(124.75M)(138.83M)(14M)(33.44M)
Income Before Tax(523.28M)(364.98M)(276.26M)(119.2M)(164.21M)
Pre-Tax Margin-513.5%-396.5%-306.5%-121.1%-297.3%
Income Tax Expense557K3.22M(200K)(239K)(138K)
Net Income(523.84M)(368.2M)(276.06M)(118.96M)(164.08M)
Net Margin-514.0%-400.0%-306.3%-120.9%-297.1%
EPS (Basic)(42.90)(29.51)(21.79)(8.68)(9.73)
EPS (Diluted)(42.90)(29.51)(21.79)(8.68)(9.73)
Weighted Avg Shares12.22M12.48M12.67M13.71M16.87M
Weighted Avg Shares (Diluted)12.22M12.48M12.67M13.71M16.87M

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$35.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.